isofagomine profile

ID Source	ID
PubMed CID	447607
CHEMBL ID	206468
CHEBI ID	194390
SCHEMBL ID	581577
MeSH ID	M0258559

Synonym
IFM ,
5-hydroxymethyl-3,4-dihydroxypiperidine
(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol
isofagomine ,
DB04545
afegostat
1OIF
CHEMBL206468 ,
AKOS006348872
(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol, 8
d-isofagomine
bdbm50182801
CHEBI:194390
169105-89-9
afegostat (usan/inn)
D09576
afegostat [usan:inn]
g23ap190ys ,
iso-fagomine
3,4-piperidinediol, 5-(hydroxymethyl)-, (3r,4r,5r)-
5-hydroxymethyl-3,4-piperidinediol
unii-g23ap190ys
gtpl7410
SCHEMBL581577
isofagomine [mi]
afegostat [who-dd]
afegostat [usan]
afegostat [inn]
QPYJXFZUIJOGNX-HSUXUTPPSA-N
DTXSID20168651
isofagomine, hydrochloride
afegostat; isofagomine; (3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol
HY-14829
CS-0003581
Q21396373

Excerpt	Reference
"Isofagomine (IFG) is an acid β-glucosidase (GCase) active site inhibitor that acts as a pharmacological chaperone. "	( Grabowski, GA; Hamler, R; Liou, B; Quinn, B; Setchell, KD; Sun, Y; Xu, YH; Zhang, W, 2012)

Class	Description
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glucocerebrosidase	Homo sapiens (human)	Potency	0.4503	0.0126	8.1569	44.6684	AID2587; AID2588; AID2589; AID2590; AID2592; AID2595; AID2596; AID2597; AID2613; AID2671; AID488845; AID488849; AID488850; AID488851; AID488852; AID488853; AID488854
Fatty-acid amide hydrolase 1	Rattus norvegicus (Norway rat)	Potency	0.6310	0.6310	16.8420	44.6684	AID2596
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Glycogen phosphorylase, muscle form	Oryctolagus cuniculus (rabbit)	Ki	5.2000	0.0250	4.8903	9.0000	AID270952
Lysosomal acid glucosylceramidase	Homo sapiens (human)	IC50 (µMol)	0.0555	0.0300	2.3589	8.8000	AID1884450; AID342801; AID500310; AID613052
Glycogen phosphorylase, liver form	Homo sapiens (human)	IC50 (µMol)	0.6850	0.0820	1.1659	4.8000	AID270950; AID342814
Glycogen phosphorylase, liver form	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.6800	0.6800	0.9267	1.1000	AID270949
Translocator protein	Rattus norvegicus (Norway rat)	Ki	5.2000	0.0001	0.6510	8.9300	AID270952
Sucrase-isomaltase, intestinal	Rattus norvegicus (Norway rat)	IC50 (µMol)	410.5000	0.0400	1.8483	10.0000	AID613047; AID613048
Beta-glucosidase	Agrobacterium tumefaciens	Ki	0.0070	0.0070	0.0070	0.0070	AID263086
Glycogen debranching enzyme	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	480.0000	0.1100	0.6975	2.1000	AID342805
Trehalose synthase/amylase TreS	Mycobacterium tuberculosis CDC1551	Ki	140.0000	0.2500	1.3750	2.5000	AID1799775
Lactase-phlorizin hydrolase	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1200	0.1200	2.9867	4.4000	AID613041
Lysosomal acid glucosylceramidase	Bos taurus (cattle)	IC50 (µMol)	31.0000	5.6000	5.6000	5.6000	AID613051
Beta-galactosidase	Bos taurus (cattle)	IC50 (µMol)	3.6000	1.5000	2.7000	3.6000	AID613054
Non-lysosomal glucosylceramidase	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0003	0.0897	0.3000	AID1408921
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Lysosomal acid glucosylceramidase	Homo sapiens (human)	INH	0.1100	0.1100	0.1100	0.1100	AID617953
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
mitochondrion organization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
neuron projection development	Lysosomal acid glucosylceramidase	Homo sapiens (human)
glucosylceramide catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
autophagy	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lysosome organization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cholesterol metabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
determination of adult lifespan	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cellular response to starvation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to pH	Lysosomal acid glucosylceramidase	Homo sapiens (human)
microglia differentiation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
regulation of macroautophagy	Lysosomal acid glucosylceramidase	Homo sapiens (human)
antigen processing and presentation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lipid storage	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cerebellar Purkinje cell layer formation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
pyramidal neuron differentiation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
respiratory electron transport chain	Lysosomal acid glucosylceramidase	Homo sapiens (human)
termination of signal transduction	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lipid glycosylation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Lysosomal acid glucosylceramidase	Homo sapiens (human)
regulation of TOR signaling	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of interleukin-6 production	Lysosomal acid glucosylceramidase	Homo sapiens (human)
T cell differentiation in thymus	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to testosterone	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of protein dephosphorylation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of protein-containing complex disassembly	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of MAP kinase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of neuron apoptotic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to estrogen	Lysosomal acid glucosylceramidase	Homo sapiens (human)
sphingosine biosynthetic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
ceramide biosynthetic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cell maturation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
brain morphogenesis	Lysosomal acid glucosylceramidase	Homo sapiens (human)
homeostasis of number of cells	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of inflammatory response	Lysosomal acid glucosylceramidase	Homo sapiens (human)
neuromuscular process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
neuron apoptotic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
establishment of skin barrier	Lysosomal acid glucosylceramidase	Homo sapiens (human)
microglial cell proliferation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
motor behavior	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cellular response to tumor necrosis factor	Lysosomal acid glucosylceramidase	Homo sapiens (human)
hematopoietic stem cell proliferation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to dexamethasone	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lymphocyte migration	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to thyroid hormone	Lysosomal acid glucosylceramidase	Homo sapiens (human)
beta-glucoside catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of protein lipidation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of neuronal action potential	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
autophagosome organization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
regulation of lysosomal protein catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
glycogen metabolic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
response to bacterium	Glycogen phosphorylase, liver form	Homo sapiens (human)
glucose homeostasis	Glycogen phosphorylase, liver form	Homo sapiens (human)
necroptotic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
glycogen catabolic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
carbohydrate metabolic process	Beta-galactosidase	Homo sapiens (human)
galactose catabolic process	Beta-galactosidase	Homo sapiens (human)
heparan sulfate proteoglycan catabolic process	Beta-galactosidase	Homo sapiens (human)
keratan sulfate catabolic process	Beta-galactosidase	Homo sapiens (human)
glycosphingolipid catabolic process	Beta-galactosidase	Homo sapiens (human)
response to cortisone	Beta-galactosidase	Homo sapiens (human)
response to Thyroglobulin triiodothyronine	Beta-galactosidase	Homo sapiens (human)
glucosylceramide catabolic process	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
autophagy	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
lysosome organization	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
cholesterol metabolic process	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
lipid glycosylation	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
regulation of TOR signaling	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
carbohydrate metabolic process	Beta-galactosidase	Bos taurus (cattle)
carbohydrate metabolic process	Non-lysosomal glucosylceramidase	Homo sapiens (human)
glucosylceramide catabolic process	Non-lysosomal glucosylceramidase	Homo sapiens (human)
cholesterol metabolic process	Non-lysosomal glucosylceramidase	Homo sapiens (human)
bile acid metabolic process	Non-lysosomal glucosylceramidase	Homo sapiens (human)
glycoside catabolic process	Non-lysosomal glucosylceramidase	Homo sapiens (human)
central nervous system neuron development	Non-lysosomal glucosylceramidase	Homo sapiens (human)
lipid glycosylation	Non-lysosomal glucosylceramidase	Homo sapiens (human)
regulation of actin filament polymerization	Non-lysosomal glucosylceramidase	Homo sapiens (human)
regulation of microtubule polymerization	Non-lysosomal glucosylceramidase	Homo sapiens (human)
glycosphingolipid catabolic process	Non-lysosomal glucosylceramidase	Homo sapiens (human)
regulation of membrane lipid distribution	Non-lysosomal glucosylceramidase	Homo sapiens (human)
central nervous system development	Non-lysosomal glucosylceramidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
galactosylceramidase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
glucosylceramidase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
signaling receptor binding	Lysosomal acid glucosylceramidase	Homo sapiens (human)
scavenger receptor binding	Lysosomal acid glucosylceramidase	Homo sapiens (human)
protein binding	Lysosomal acid glucosylceramidase	Homo sapiens (human)
glucosyltransferase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
steryl-beta-glucosidase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
purine nucleobase binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
protein binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
ATP binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
glucose binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
glycogen phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
AMP binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
vitamin binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
bile acid binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
identical protein binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
linear malto-oligosaccharide phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
SHG alpha-glucan phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
pyridoxal phosphate binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
beta-galactosidase activity	Beta-galactosidase	Homo sapiens (human)
protein binding	Beta-galactosidase	Homo sapiens (human)
galactoside binding	Beta-galactosidase	Homo sapiens (human)
protein homodimerization activity	Beta-galactosidase	Homo sapiens (human)
galactosylceramidase activity	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
glucosylceramidase activity	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
glucosyltransferase activity	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
steryl-beta-glucosidase activity	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
beta-galactosidase activity	Beta-galactosidase	Bos taurus (cattle)
galactosylceramidase activity	Non-lysosomal glucosylceramidase	Homo sapiens (human)
glucosylceramidase activity	Non-lysosomal glucosylceramidase	Homo sapiens (human)
beta-glucosidase activity	Non-lysosomal glucosylceramidase	Homo sapiens (human)
glucosyltransferase activity	Non-lysosomal glucosylceramidase	Homo sapiens (human)
steryl-beta-glucosidase activity	Non-lysosomal glucosylceramidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
lysosome	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lysosomal membrane	Lysosomal acid glucosylceramidase	Homo sapiens (human)
endoplasmic reticulum	Lysosomal acid glucosylceramidase	Homo sapiens (human)
Golgi apparatus	Lysosomal acid glucosylceramidase	Homo sapiens (human)
trans-Golgi network	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lysosomal lumen	Lysosomal acid glucosylceramidase	Homo sapiens (human)
extracellular exosome	Lysosomal acid glucosylceramidase	Homo sapiens (human)
extracellular region	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytosol	Glycogen phosphorylase, liver form	Homo sapiens (human)
secretory granule lumen	Glycogen phosphorylase, liver form	Homo sapiens (human)
extracellular exosome	Glycogen phosphorylase, liver form	Homo sapiens (human)
ficolin-1-rich granule lumen	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytoplasm	Glycogen phosphorylase, liver form	Homo sapiens (human)
extracellular region	Beta-galactosidase	Homo sapiens (human)
cytoplasm	Beta-galactosidase	Homo sapiens (human)
Golgi apparatus	Beta-galactosidase	Homo sapiens (human)
azurophil granule lumen	Beta-galactosidase	Homo sapiens (human)
lysosomal lumen	Beta-galactosidase	Homo sapiens (human)
intracellular membrane-bounded organelle	Beta-galactosidase	Homo sapiens (human)
perinuclear region of cytoplasm	Beta-galactosidase	Homo sapiens (human)
extracellular exosome	Beta-galactosidase	Homo sapiens (human)
ficolin-1-rich granule lumen	Beta-galactosidase	Homo sapiens (human)
vacuole	Beta-galactosidase	Homo sapiens (human)
lysosome	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
lysosomal membrane	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
endoplasmic reticulum	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
Golgi apparatus	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
trans-Golgi network	Lysosomal acid glucosylceramidase	Bos taurus (cattle)
lysosome	Beta-galactosidase	Bos taurus (cattle)
Golgi membrane	Non-lysosomal glucosylceramidase	Homo sapiens (human)
endoplasmic reticulum membrane	Non-lysosomal glucosylceramidase	Homo sapiens (human)
smooth endoplasmic reticulum	Non-lysosomal glucosylceramidase	Homo sapiens (human)
cytosol	Non-lysosomal glucosylceramidase	Homo sapiens (human)
plasma membrane	Non-lysosomal glucosylceramidase	Homo sapiens (human)
membrane	Non-lysosomal glucosylceramidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (87)

Assay ID	Title	Year	Journal	Article
AID577516	Binding affinity to recombinant Gcase assessed as change in melting temperature at 500 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577335	Increase of GCase N370S mutant trafficking to lysosomes in human fibroblast cells assessed as colocalization of Gcase with Lamp2 at 1 uM after 5 days by immunofluorescence method	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID1408923	Chaperone activity at beta-galactosidase p.H281Y mutant in Zurich2 fibroblasts derived from GM1-gangliosidosis patient assessed as increase in enzyme activity using 4-methylumbelliferyl beta-D-galactopyranoside as substrate preincubated for 2 days followe	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
AID342972	Inhibition of basal glycogen degradation in hepatocytes	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID1601617	Activation of lysosomal beta-glucocerebrosidase N370S mutant in fibroblast cells derived from Gaucher's disease patient at 5 uM using PFB-FDGlu as substrate preincubated for 3 days followed by substrate addition and measured after 1 hr for every 20 mins i	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.
AID1408921	Inhibition of beta-glucosidase derived from human peripheral blood mononuclear cell lysate using 4-methylumbelliferyl beta-D-glucopyranoside as substrate after 2 hrs by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
AID270951	Binding affinity to non-phosphorylated form of rabbit muscle glycogen phosphorylase at 50 mM in absence of phosphate	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID270948	Inhibition of phosphorylated form of rabbit muscle glycogen phosphorylase	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID613050	Inhibition of rat intestinal cellobiase assessed as production of p-nitrophenol by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID500310	Inhibition of GCase assessed as 4-methylumbelliferone release assay after 30 mins by fluorimetry	2007	Nature chemical biology, Feb, Volume: 3, Issue:2	Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
AID620279	Inhibition of sweet almond beta-glucosidase	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	Synthesis of new six- and seven-membered 1-N-iminosugars as promising glycosidase inhibitors.
AID342800	Inhibition of human lysosomal alpha-glucosidase at 1000 uM	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID613054	Inhibition of bovine liver beta-galactosidase assessed as production of p-nitrophenol by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID731610	Induction of beta glucosidase L444P mutant activity in fibroblasts derived from Gaucher disease patient using 4MUG as substrate relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID577524	Binding affinity to recombinant Gcase assessed as change in melting temperature at 1 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID1321666	Activation of GCase N370S mutant in human Gaucher disease patient fibroblasts assessed as increase in GCase protein levels at 20 and 50 uM measured after 3 days by immunoblot analysis	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase Modulators.
AID270952	Inhibition of non-phosphorylated form of rabbit muscle glycogen phosphorylase in presence of phosphate	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID613046	Inhibition of rat intestinal maltase assessed as production of D-glucose using maltose as substrate after 10 to 30 mins by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID731607	Induction of beta glucosidase L444P mutant in mouse brain administered with drinking water measured after 4 weeks relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID613039	Inhibition of coffee beans alpha-galactosidase assessed as production of p-nitrophenol at 1000 uM by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID342812	Increase in lysosomal beta-glucosidase N370S mutant activity in human Gaucher GM00372 fibroblast at 10 uM after 4 days	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID342801	Inhibition of human lysosomal beta-glucosidase	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID577514	Inhibition of alpha-galactosidase	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID1125778	Increase of intracellular activity of beta-glucocerebrosidase in human N370S cells using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate at 50 uM after 4 days relative to control	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Docking and SAR studies of calystegines: binding orientation and influence on pharmacological chaperone effects for Gaucher's disease.
AID1408920	Inhibition of alpha-galactosidase derived from human peripheral blood mononuclear cell lysate using 4-methylumbelliferyl alpha-D-galactopyranoside as substrate after 2 hrs by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
AID731621	Induction of beta glucosidase N370S mutant activity in primary skin fibroblast derived from Gaucher disease patient at 30 uM after 5 days relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID613051	Inhibition of bovine liver beta-glucosidase assessed as production of 4-methylumbelliferone using 4-methylumbelliferyl beta-D-glucoside as substrate by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID613041	Inhibition of rat intestinal lactase assessed as production of p-nitrophenol by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID1321660	Binding affinity to synthetic recombinant wild type GCase enzyme velaglucerase alfa (unknown origin) assessed as thermal stabilization measured as increase in melting temperature at pH 5 measured every 10 secs by Sypro Orange-dye based fluorescence therma	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase Modulators.
AID500313	Restoration of GCase N370S mutant trafficking to lysosomes in human DMN89.15 fibroblast cells assessed as colocalization of Gcase with Lamp1 at 100 uM after 5 days by immunofluorescence method	2007	Nature chemical biology, Feb, Volume: 3, Issue:2	Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
AID617946	Inhibition of alpha-glucosidase	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Synthesis and glycosidase inhibitory profiles of functionalised morpholines and oxazepanes.
AID577520	Binding affinity to recombinant Gcase assessed as change in melting temperature at 100 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577333	Binding affinity to recombinant Gcase assessed as change in melting temperature by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID270950	Inhibition of phosphorylated form of pig liver glycogen phosphorylase	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID617953	Inhibition of beta-glucosidase	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	Synthesis and glycosidase inhibitory profiles of functionalised morpholines and oxazepanes.
AID1601619	Activation of lysosomal beta-glucocerebrosidase activity in human healthy fibroblast cells at 5 uM using PFB-FDGlu as substrate preincubated for 3 days followed by substrate addition and measured after 1 hr for every 20 mins in presence of bafilomycin by	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.
AID579819	Activation of beta-glucocerebrosidase in human N370S cells assessed as decrease of residual activity at 0.05 to 100 uM after 3 days	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.
AID577332	Increase of GCase trafficking to lysosomes in human fibroblast cells assessed as colocalization of Gcase with Lamp2 at 10 uM after 5 days by immunofluorescence method	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID731611	Induction of beta glucosidase N370S mutant activity in fibroblast derived from Gaucher disease patient at 10 to 50 uM relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1412120	Chaperone activity at GBA N370S mutant in Gaucher disease patient-derived fibroblasts assessed as restoration of enzyme activity at 1 to 10000 nM after 4 days by 4-methylumbelliferyl-beta-D-glucopyranoside substrate based fluorescence assay	2017	MedChemComm, Nov-01, Volume: 8, Issue:11	Orthoester functionalized
AID270958	Inhibition of glucagon-stimulated glycogen degradation in hepatocytes	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID577525	Binding affinity to recombinant Gcase assessed as change in melting temperature at 0.1 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID731595	Induction of beta glucosidase N370S mutant activity in fibroblasts derived from Gaucher disease type 1 patient at 30 uM relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1601618	Activation of lysosomal beta-glucocerebrosidase L444P mutant in fibroblast cells derived from Gaucher's disease patient at 5 uM using PFB-FDGlu as substrate preincubated for 3 days followed by substrate addition and measured after 1 hr for every 20 mins i	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.
AID613042	Inhibition of jack beans alpha-mannosidase assessed as production of p-nitrophenol at 1000 uM by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID1884450	Inhibition of human GCase assessed as reduction of 4-methylumbelliferone liberation using 4-methylumbelliferyl-beta-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition by fluorescence spectrophotometry	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
AID577521	Binding affinity to recombinant Gcase assessed as change in melting temperature at 50 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID613043	Inhibition of snail beta-mannosidase assessed as production of p-nitrophenol at 1000 uM by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID1119120	Inhibition of glucocerebrosidase N370S mutant in spleen homogenates of patient with Gaucher disease using resorufin-beta-D-glucopyranoside as substrate after 20 mins fluorescence assay	2012	MedChemComm, Jan, Volume: 3, Issue:1	Non-iminosugar glucocerebrosidase small molecule chaperones.
AID1408922	Inhibition of beta-galactosidase derived from human peripheral blood mononuclear cell lysate using 4-methylumbelliferyl beta-D-galactopyranoside as substrate after 2 hrs by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
AID497872	Inhibition of wild type Bacteroides thetaiotaomicron beta-mannosidase 2A expressed in Escherichia coli BL21 (DE3) at 37 degC and Ph 5.6 by 2,4-dinitrophenolate release assay	2008	Nature chemical biology, May, Volume: 4, Issue:5	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
AID342796	Inhibition of rat intestinal brush border membrane isomaltase at 1000 uM	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID342805	Inhibition of rabbit muscle amylo-1,6-glucosidase	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID577336	Increase of GCase trafficking to lysosomes in human fibroblast cells assessed as colocalization of Gcase with Lamp2 at 1 uM after 5 days by immunofluorescence method	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577519	Binding affinity to recombinant Gcase assessed as change in melting temperature at 200 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID500311	Increase in Gcase N370S mutant activity in human DMN89.15 fibroblast cell lysate assessed as 4-methylumbelliferone release after 5 days by fluorimetry	2007	Nature chemical biology, Feb, Volume: 3, Issue:2	Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
AID270949	Inhibition of phosphorylated form of rat liver glycogen phosphorylase	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID613052	Inhibition of human lysosome beta-glucosidase assessed as production of 4-methylumbelliferone using 4-methylumbelliferyl beta-D-glucoside as substrate by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID613047	Inhibition of rat intestinal isomaltase assessed as production of p-nitrophenol at by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID342794	Inhibition of rat intestinal brush border membrane maltase at 1000 uM	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID577518	Binding affinity to recombinant Gcase assessed as change in melting temperature at 300 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID270947	Inhibition of non-phosphorylated form of rabbit muscle glycogen phosphorylase	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID342803	Inhibition of rabbit glycogen phosphorylase B	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID342813	Increase in lysosomal beta-glucosidase N370S mutant activity in human Gaucher GM00372 fibroblast at 500 uM after 4 days	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID577522	Binding affinity to recombinant Gcase assessed as change in melting temperature at 25 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID263086	Inhibition of Agrobacterium sp. beta-glucosidase	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Fluorescent glycosidase inhibiting 1,5-dideoxy-1,5-iminoalditols.
AID577517	Binding affinity to recombinant Gcase assessed as change in melting temperature at 400 uM by fluorescence thermal shift technique	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID1601620	Induction of post-ER GCase activity in fibroblast cells harboring N370S/84GG double mutant derived from Gaucher's disease patient at 25 uM using PFB-FDGlu as substrate preincubated for 3 days followed by substrate addition and measured after 1 hr for ever	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.
AID1408919	Inhibition of alpha-glucosidase derived from human peripheral blood mononuclear cell lysate using 4-methylumbelliferyl alpha-D-glucopyranoside as substrate after 2 hrs by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
AID613031	Inhibition of rice alpha-glucosidase assessed as production of D-glucose using maltose as substrate at 1000 uM after 10 to 30 mins by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID613045	Inhibition of Penicillium decumbens alpha-L-rhamnosidase assessed as production of p-nitrophenol at 1000 uM by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID577331	Increase of GCase N370S mutant trafficking to lysosomes in human fibroblast cells assessed as colocalization of Gcase with Lamp2 at 10 uM after 5 days by immunofluorescence method	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID342973	Inhibition of glucagon-stimulated glycogen degradation in hepatocytes	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID613044	Inhibition of bovine epididymis alpha-L-fucosidase assessed as production of p-nitrophenol at 1000 uM by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID577513	Inhibition of alpha-glucosidase	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID500312	Induction of Gcase N370S mutant distribution in human DMN89.15 fibroblast cells at 100 uM after 5 days by antibody staining based laser scanning confocal microscopy	2007	Nature chemical biology, Feb, Volume: 3, Issue:2	Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
AID342798	Inhibition of rat intestinal brush border membrane sucrase at 1000 uM	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID613048	Inhibition of rat intestinal sucrase assessed as production of p-nitrophenol at by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID1119122	Induction of glucocerebrosidase N370S mutant translocation in fibroblasts of patient with Gaucher disease assessed as co-localization of LAMP-1 in lysosomes at 1 uM after 5 days by laser scanning confocal microscopic analysis	2012	MedChemComm, Jan, Volume: 3, Issue:1	Non-iminosugar glucocerebrosidase small molecule chaperones.
AID342814	Inhibition of liver glycogen phosphorylase A	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID270957	Inhibition of glycogen degradation in hepatocytes	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
AID1408924	Cytotoxicity against human GM02456 fibroblasts after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
AID613049	Inhibition of almond beta-glucosidase assessed as production of 4-methylumbelliferone using 4-methylumbelliferyl beta-D-glucoside as substrate by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.
AID731609	Induction of beta glucosidase N370S mutant activity in fibroblast derived from Gaucher disease patient at 10 uM relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1601621	Induction of post-ER GCase level in fibroblast cells harboring N370S/84GG double mutant derived from Gaucher's disease patient at 25 uM by immunoblotting analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.
AID1799390	Btman2A from Article 10.1038/nchembio.81: \\Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.\\	2008	Nature chemical biology, May, Volume: 4, Issue:5	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
AID1799775	Inhibition Assay from Article 10.1074/jbc.M111.280362: \\Mechanistic analysis of trehalose synthase from Mycobacterium smegmatis.\\	2011	The Journal of biological chemistry, Oct-14, Volume: 286, Issue:41	Mechanistic analysis of trehalose synthase from Mycobacterium smegmatis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (3.19)	18.2507
2000's	41 (43.62)	29.6817
2010's	46 (48.94)	24.3611
2020's	4 (4.26)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (3.16%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	92 (96.84%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
1-deoxynojirimycin	[no description available]	medium	18	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
1-deoxymannojirimycin	[no description available]	medium	2
2-acetamido-1,5-imino-1,2,5-trideoxy-d-glucitol	[no description available]	medium	2
deoxyfuconojirimycin	[no description available]	medium	1	hydroxypiperidine; triol	fungal metabolite
migalastat	[no description available]	medium	2	piperidines
miglustat	[no description available]	medium	6	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
castanospermine	[no description available]	medium	3	indolizidine alkaloid	anti-HIV-1 agent; anti-inflammatory agent; EC 3.2.1.* (glycosidase) inhibitor; metabolite
1,2,3,4-tetrahydroxy-nor-tropane	[no description available]	medium	3
fagomine	[no description available]	medium	3	piperidines
homonojirimycin	[no description available]	medium	2
valiolamine	[no description available]	medium	1
miglitol	[no description available]	medium	1	piperidines
ao 128	[no description available]	medium	1	organic molecular entity
acarbose	[no description available]	medium	1	amino cyclitol; glycoside
1,4-dideoxy-1,4-imino-d-arabinitol	[no description available]	medium	2
4-[4-(4-methylphenyl)sulfonyl-1-piperazinyl]-2-thiophen-2-ylquinazoline	[no description available]	medium	1	sulfonamide
n-nonyl-1-deoxynojirimycin	[no description available]	medium	3	hydroxypiperidine; tertiary amino compound	antiviral agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.2.1.45 (glucosylceramidase) inhibitor
3-epi-fagomine	[no description available]	medium	1	amino monosaccharide; hydroxypiperidine; primary alcohol; secondary alcohol; secondary amino compound; triol	EC 3.2.1.10 (oligo-1,6-glucosidase) inhibitor; EC 3.2.1.23 (beta-galactosidase) inhibitor; plant metabolite
casuarine	[no description available]	medium	1
nnc 26-9100	[no description available]	medium	1	aminopyridine
1-(3-aminopropyl)-3-[3-[(5-bromo-2-pyridinyl)-[(4-chlorophenyl)methyl]amino]propyl]thiourea	[no description available]	medium	1	aminopyridine
1-[3-[(5-bromo-2-pyridinyl)-[(4-chlorophenyl)methyl]amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea	[no description available]	medium	1	aminopyridine
1-[3-[(5-bromo-2-pyridinyl)-(phenylmethyl)amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea	[no description available]	medium	1	aminopyridine
1-[3-[(5-bromo-2-pyridinyl)-butylamino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea	[no description available]	medium	1	dialkylarylamine; tertiary amino compound
N-[3-[[[3-[(5-bromo-2-pyridinyl)-[(4-chlorophenyl)methyl]amino]propylamino]-sulfanylidenemethyl]amino]propyl]acetamide	[no description available]	medium	1	aminopyridine
1-[4-[(5-bromo-2-pyridinyl)-[(4-chlorophenyl)methyl]amino]butyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea	[no description available]	medium	1	aminopyridine
ambroxol	[no description available]	medium	3	aromatic amine
galactose	[no description available]	medium	3	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
diltiazem	[no description available]	medium	2	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
lobeline	[no description available]	medium	1	aromatic ketone; piperidine alkaloid; tertiary amine	nicotinic acetylcholine receptor agonist
glucosamine	[no description available]	medium	4	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
4-(benzenesulfonamido)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide	[no description available]	medium	1	sulfonamide
N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide	[no description available]	medium	1	aminoquinoline
n-acetylglucosamine thiazoline	[no description available]	medium	1
n-octyl-beta-valienamine	[no description available]	medium	1
calystegine a3	[no description available]	medium	1
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine	[no description available]	medium	1	aromatic amine; piperidines; pyridines; quinazolines; secondary amino compound; tertiary amino compound
phenanthrenes	[no description available]	medium	1
cyclopentane	[no description available]	medium	1	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
irinotecan	[no description available]	medium	1	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
lactic acid	[no description available]	medium	2	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
arabinose	[no description available]	medium	4	L-arabinose	Escherichia coli metabolite; mouse metabolite
1,4-dideoxy-1,4-iminoarabinitol	[no description available]	medium	1
piperidines	[no description available]	medium	40
pyrrolidine	[no description available]	medium	2	azacycloalkane; pyrrolidines; saturated organic heteromonocyclic parent
piperidine	[no description available]	medium	1	azacycloalkane; piperidines; saturated organic heteromonocyclic parent; secondary amine	base; catalyst; human metabolite; non-polar solvent; plant metabolite; protic solvent; reagent
xylitol	[no description available]	medium	1
alpha-synuclein	[no description available]	medium	1
psychosine	[no description available]	medium	2	glycosylsphingoid	human metabolite
sphingosyl beta-glucoside	[no description available]	medium	2
ruthenium	[no description available]	medium	1	iron group element atom; platinum group metal atom
verapamil	[no description available]	medium	1	aromatic ether; nitrile; polyether; tertiary amino compound
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene	[no description available]	medium	2	BODIPY compound
cyclophellitol	[no description available]	medium	1
cyclohexanol	[no description available]	medium	1	cyclohexanols; secondary alcohol	solvent
cellulase	[no description available]	medium	3	cellotriose
ether	[no description available]	medium	1	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
deuterium	[no description available]	medium	1	dihydrogen
hydrogen	[no description available]	medium	1	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
glycosides	[no description available]	medium	1
xylobiose	[no description available]	medium	3	glycosylxylose	bacterial metabolite
cellobiose	[no description available]	medium	1	cellobiose	epitope
fucose	[no description available]	medium	1	fucopyranose; L-fucose	Escherichia coli metabolite; mouse metabolite
glycogen	[no description available]	medium	3
3-nitrotyrosine	[no description available]	medium	1	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
tyrosine	[no description available]	medium	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
serine	[no description available]	medium	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
sodium dodecyl sulfate	[no description available]	medium	1	organic sodium salt	detergent; protein denaturant
asparagine	[no description available]	medium	1	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
adamantane	[no description available]	medium	1	adamantanes; polycyclic alkane
sorbitol	[no description available]	medium	1	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
imidazole	[no description available]	medium	1	imidazole
1-azafagomine	[no description available]	medium	2
methyl nicotinate	[no description available]	medium	1	aromatic carboxylic acid; pyridines
glucose, (beta-d)-isomer	[no description available]	medium	1	D-glucopyranose	epitope; mouse metabolite
astemizole	[no description available]	low	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
biperiden	[no description available]	low	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
clebopride	[no description available]	low	0	piperidines
cycrimine	[no description available]	low	0	piperidines; tertiary alcohol; tertiary amino compound	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
cyproheptadine	[no description available]	low	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
diphenidol	[no description available]	low	0	benzenes; piperidines; tertiary alcohol	antiemetic
diphenylpyraline	[no description available]	low	0	piperidines; tertiary amine	cholinergic antagonist; H1-receptor antagonist
dipyridamole	[no description available]	low	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
donepezil	[no description available]	low	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
dyclonine	[no description available]	low	0	aromatic ketone; piperidines	topical anaesthetic
eperisone	[no description available]	low	0	aromatic ketone; piperidines
ethyl piperidinoacetylaminobenzoate	[no description available]	low	0	benzoate ester; piperidines
fentanyl	[no description available]	low	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fexofenadine	[no description available]	low	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
flavoxate	[no description available]	low	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
flecainide	[no description available]	low	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
glutethimide	[no description available]	low	0	piperidines
ifenprodil	[no description available]	low	0	piperidines
ketanserin	[no description available]	low	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketotifen	[no description available]	low	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
loperamide	[no description available]	low	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
mazaticol	[no description available]	low	0	piperidines
mefloquine hydrochloride	[no description available]	low	0	organofluorine compound; piperidines; quinolines; secondary alcohol
methylphenidate	[no description available]	low	0	beta-amino acid ester; methyl ester; piperidines
methixene	[no description available]	low	0	piperidines; thioxanthenes	antiparkinson drug; histamine antagonist; muscarinic antagonist
perhexiline	[no description available]	low	0	piperidines	cardiovascular drug
pridinol	[no description available]	low	0	piperidines; tertiary alcohol	antiparkinson drug; muscle relaxant
ritanserin	[no description available]	low	0	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
roxatidine acetate	[no description available]	low	0	piperidines
sb 220025	[no description available]	low	0	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
spiperone	[no description available]	low	0	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
thioridazine	[no description available]	low	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
tipepidine	[no description available]	low	0	piperidines
vesamicol	[no description available]	low	0	piperidines
diphemanil methylsulfate	[no description available]	low	0	piperidines; quaternary ammonium salt	bronchodilator agent; muscarinic antagonist; parasympatholytic
phencyclidine	[no description available]	low	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
pempidine	[no description available]	low	0	piperidines
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester	[no description available]	low	0	piperidines
2-methylpiperidine	[no description available]	low	0	piperidines
jervine	[no description available]	low	0	piperidines
ketobemidone	[no description available]	low	0	piperidines
phenoperidine	[no description available]	low	0	piperidines
benzetimide	[no description available]	low	0	piperidines
piminodine	[no description available]	low	0	piperidines
dexetimide	[no description available]	low	0	piperidines
4-(4-chlorophenyl)-4-hydroxypiperidine	[no description available]	low	0	piperidines
sufentanil	[no description available]	low	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
paroxetine	[no description available]	low	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
encainide	[no description available]	low	0	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker
alfentanil	[no description available]	low	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
levocabastine	[no description available]	low	0	piperidines
preclamol	[no description available]	low	0	piperidines
loxtidine	[no description available]	low	0	aromatic ether; piperidines; primary alcohol; triazoles	H2-receptor antagonist
tzu 0460	[no description available]	low	0	piperidines
eliprodil	[no description available]	low	0	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
tirofiban	[no description available]	low	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
3-methylfentanyl	[no description available]	low	0	monocarboxylic acid amide; piperidines	mu-opioid receptor agonist; opioid analgesic; sedative
carfentanil	[no description available]	low	0	methyl ester; piperidines; tertiary amino compound; tertiary carboxamide	mu-opioid receptor agonist; opioid analgesic; tranquilizing drug
f 7302	[no description available]	low	0	piperidines
4-fluorofentanyl	[no description available]	low	0	monocarboxylic acid amide; organofluorine compound; piperidines
tenocyclidine	[no description available]	low	0	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist
terikalant	[no description available]	low	0	piperidines
repaglinide	[no description available]	low	0	piperidines
spiramide	[no description available]	low	0	aromatic ether; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; serotonergic antagonist
hp 873	[no description available]	low	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
sufotidine	[no description available]	low	0	piperidines
1-(4-nitrophenyl)piperidine	[no description available]	low	0	piperidines
fentanyl isothiocyanate	[no description available]	low	0	piperidines
ritalinic acid	[no description available]	low	0	monocarboxylic acid; piperidines	drug metabolite; marine xenobiotic metabolite
fenpropidine	[no description available]	low	0	piperidines; tertiary amine
sk&f 95282	[no description available]	low	0	piperidines
biperiden hydrochloride	[no description available]	low	0	hydrochloride; piperidines; tertiary alcohol	antiparkinson drug; muscarinic antagonist; parasympatholytic
phenglutarimide	[no description available]	low	0	piperidines
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol	[no description available]	low	0	piperidines
gr 113808	[no description available]	low	0	indolyl carboxylate ester; piperidines; sulfonamide	serotonergic antagonist
alphaprodine	[no description available]	low	0	piperidines
lofentanil	[no description available]	low	0	methyl ester; piperidines; tertiary amino compound; tertiary carboxamide	mu-opioid receptor agonist; opioid analgesic
1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine	[no description available]	low	0	1-benzothiophenes; piperidines; tertiary amino compound	dopamine uptake inhibitor
picaridin	[no description available]	low	0	carboxylic acid; piperidines
5-(4-piperidyl)isoxazol-3-ol	[no description available]	low	0	piperidines
ku 1257	[no description available]	low	0	piperidines
l 733060	[no description available]	low	0	piperidines
n-(n-benzylpiperidin-4-yl)-4-iodobenzamide	[no description available]	low	0	piperidines
l 741626	[no description available]	low	0	piperidines
aminopotentidine	[no description available]	low	0	aromatic ether; benzamides; guanidines; nitrile; piperidines; substituted aniline	H2-receptor antagonist
zanapezil	[no description available]	low	0	piperidines
anacoline iodide	[no description available]	low	0	dioxolane; piperidines
norfentanyl	[no description available]	low	0	anilide; monocarboxylic acid amide; piperidines	drug metabolite; opioid analgesic
magellanine	[no description available]	low	0	piperidines
tecomine	[no description available]	low	0	piperidines
cyclopamine	[no description available]	low	0	piperidines	glioma-associated oncogene inhibitor
efinaconazole	[no description available]	low	0	conazole antifungal drug; olefinic compound; organofluorine compound; piperidines; tertiary alcohol; tertiary amino compound; triazole antifungal drug	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
N-(1,3-benzodioxol-5-yl)-1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinecarboxamide	[no description available]	low	0	piperidines
N-(1-adamantyl)-4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinecarboxamide	[no description available]	low	0	piperidines
2-[(1,3-dimethyl-2,6-dioxo-7-propyl-8-purinyl)thio]-N-[2-(1-piperidinyl)phenyl]acetamide	[no description available]	low	0	piperidines
4-methyl-N-[3-[1-(phenylmethyl)-4-piperidinyl]-2,4-dihydro-1H-1,3,5-triazin-6-yl]benzenesulfonamide	[no description available]	low	0	piperidines
4-(2-benzamidoethylamino)-1-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	carboxylic acid; piperidines
N-[3-(dimethylamino)-2,2-dimethylpropyl]-1-[(2-hydroxyphenyl)methyl]-4-piperidinecarboxamide	[no description available]	low	0	piperidines
N-(2-ethoxyphenyl)-1-[4-(1-pyrrolidinylsulfonyl)phenyl]-4-piperidinecarboxamide	[no description available]	low	0	piperidines
1-(4,6-dimethyl-2-pyrimidinyl)-4-piperidinecarboxylic acid	[no description available]	low	0	carboxylic acid; piperidines
N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamide	[no description available]	low	0	acetamides; piperidines; pyridines; sulfonamide
1-(1-oxo-2-thiophen-2-ylethyl)-4-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	carboxylic acid; piperidines
4-Piperidinobenzoic acid	[no description available]	low	0	piperidines
N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine	[no description available]	low	0	piperidines; quinazolines; tertiary amino compound; toluenes
2-(2-methylphenoxy)-N-[2-(4-methyl-1-piperidinyl)phenyl]acetamide	[no description available]	low	0	piperidines
2-(phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile	[no description available]	low	0	piperidines
1-(phenylmethyl)-N'-(2,4,6-trimethylphenyl)sulfonyl-4-piperidinecarbohydrazide	[no description available]	low	0	piperidines
1-[2-[(4-methyl-2-oxo-1-benzopyran-7-yl)oxy]-1-oxoethyl]-4-phenyl-4-piperidinecarboxylic acid	[no description available]	low	0	piperidines
3-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-1,3-diazaspiro[4.6]undecane-2,4-dione	[no description available]	low	0	piperidines
1-[1-(phenylmethyl)-4-piperidinyl]-3-(2,4,4-trimethylpentan-2-yl)thiourea	[no description available]	low	0	piperidines
4-[4-(phenylmethyl)-1-piperidinyl]thieno[2,3-d]pyrimidine	[no description available]	low	0	piperidines; thienopyrimidine
cyclohexanecarboxylic acid [2-oxo-2-[4-(1-piperidinyl)anilino]ethyl] ester	[no description available]	low	0	piperidines
1-[1-(phenylmethyl)-4-piperidinyl]-3-(2-propan-2-ylphenyl)thiourea	[no description available]	low	0	piperidines
1-(4-ethylphenyl)-3-[1-(phenylmethyl)-4-piperidinyl]thiourea	[no description available]	low	0	piperidines
tempo	[no description available]	low	0	aminoxyls; piperidines	catalyst; ferroptosis inhibitor; radical scavenger
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl	[no description available]	low	0	aminoxyls; dicarboximide; maleimides; piperidines	radical scavenger; spin label
N-(4-bromophenyl)-4-(2-methoxyphenyl)-1-piperidinecarbothioamide	[no description available]	low	0	piperidines
N1-(1-benzyl-4-piperidyl)-4-chlorobenzene-1-sulfonamide	[no description available]	low	0	piperidines
3,3-dimethyl-1-[4-(trifluoromethoxy)phenyl]piperidine-2,6-dione	[no description available]	low	0	piperidines
1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]piperidine	[no description available]	low	0	piperidines
4-(benzenesulfonyl)-1-[(4-chlorophenyl)methyl]-4-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	piperidines
2-benzyl-6-hydroxy-2-azabicyclo[2.2.2]octan-3-one	[no description available]	low	0	piperidines
5-methyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-thieno[2,3-d]pyrimidinamine	[no description available]	low	0	piperidines; thienopyrimidine
N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N'-(4-fluorophenyl)urea	[no description available]	low	0	piperidines
[4-(2-methoxyphenyl)-1-piperidinyl]-(5-methyl-1-phenyl-4-pyrazolyl)methanone	[no description available]	low	0	piperidines
4-acetamidobenzenesulfonic acid [2-(1-piperidinyl)phenyl] ester	[no description available]	low	0	piperidines
1-(3-phenylpropanoyl)-4-piperidinecarboxylic acid	[no description available]	low	0	carboxylic acid; piperidines
4-fluoro-N-[2-(1-piperidinyl)phenyl]benzenesulfonamide	[no description available]	low	0	piperidines
1-(2-fluorophenyl)-3-[2-(1-piperidinyl)phenyl]urea	[no description available]	low	0	piperidines
4-(1-piperidinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonylamino]benzoic acid ethyl ester	[no description available]	low	0	piperidines
1-[(3-chlorophenyl)methyl]-N,N-diethyl-3-piperidinecarboxamide	[no description available]	low	0	piperidines
3-hydroxy-5-nitro-2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-triazolimine	[no description available]	low	0	piperidines
1-(3-chlorophenyl)-3-[[1-[(2,5-dimethoxyphenyl)methyl]-4-piperidinyl]methyl]urea	[no description available]	low	0	piperidines
1-[2-hydroxy-3-[4-(2-methylbutan-2-yl)phenoxy]propyl]-4-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	carboxylic acid; piperidines
femoxetine	[no description available]	low	0	piperidines
4-phenyl-1-(4-phenylbutyl)piperidine	[no description available]	low	0	piperidines
4-(1h-imidazol-4-ylmethyl)piperidine	[no description available]	low	0	piperidines
tandutinib	[no description available]	low	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
zd 6474	[no description available]	low	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
6-phenylspiro[7-oxa-1-azabicyclo[2.2.1]heptane-2,1'-cyclopentane]	[no description available]	low	0	piperidines
3,5-dimethyl-2,6-bis(4-methylphenyl)-4-piperidinone	[no description available]	low	0	piperidines
1-[2-[(4-chlorophenyl)thio]-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	carboxylic acid; piperidines
1-[9-[(4-fluorophenyl)methyl]-9-azabicyclo[3.3.1]nonan-3-yl]-3-(2-phenylphenyl)urea	[no description available]	low	0	piperidines
4-(2-fluorophenyl)-1-[[1-[(4-methoxyphenyl)methyl]-5-tetrazolyl]methyl]-4-piperidinol	[no description available]	low	0	piperidines
1-(3-methylphenyl)-3-[[1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinyl]methyl]urea	[no description available]	low	0	piperidines
1-(2-methylphenyl)-3-[[1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinyl]methyl]urea	[no description available]	low	0	piperidines
1-[2-[3-(N-ethylanilino)propylamino]-3,4-dioxo-1-cyclobutenyl]-4-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	carboxylic acid; piperidines
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[(3,4-dimethoxyphenyl)methyl]-N-methyl-3-piperidinecarboxamide	[no description available]	low	0	piperidines
4-[[2-(3-ethylanilino)-3,4-dioxo-1-cyclobutenyl]amino]-1-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	carboxylic acid; piperidines
1,4-dimethyl-6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]quinoxaline-2,3-dione	[no description available]	low	0	piperidines
1-[(3-chlorophenyl)methyl]-N-methyl-N-(phenylmethyl)-3-piperidinecarboxamide	[no description available]	low	0	piperidines
4-[4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-piperidinyl]-3-nitrobenzoic acid methyl ester	[no description available]	low	0	piperidines
benzoic acid [[1-(4-nitrophenyl)-4-piperidinylidene]amino] ester	[no description available]	low	0	piperidines
1-[(4-chlorophenyl)methyl]-4-(4-chlorophenyl)sulfonyl-4-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	piperidines
1-[3-[(2-methoxyphenyl)sulfamoyl]-4-(1-piperidinyl)phenyl]-3-(3-methylphenyl)urea	[no description available]	low	0	piperidines
1-[(6-hydroxy-2-methyl-5-thiazolo[3,2-b][1,2,4]triazolyl)-(3,4,5-trimethoxyphenyl)methyl]-4-piperidinecarboxylic acid methyl ester	[no description available]	low	0	carboxylic acid; piperidines
1-pyrrolidinyl-[1-[(2,3,4-trimethoxyphenyl)methyl]-3-piperidinyl]methanone	[no description available]	low	0	piperidines
2-[1-[4-(diethylamino)phenyl]-4a-hydroxy-1,3,4,5,6,7,8,8a-octahydroisoquinolin-2-yl]-N-phenylacetamide	[no description available]	low	0	piperidines
2-(hexylamino)-1-[4-(phenylmethyl)-1-piperidinyl]ethanone	[no description available]	low	0	piperidines
LY-310762	[no description available]	low	0	aromatic ketone; monofluorobenzenes; oxindoles; piperidines; tertiary amino compound	receptor modulator; serotonergic antagonist
5-(4-morpholinylsulfonyl)-2-(1-piperidinyl)benzoic acid [2-[[(3-methylbutylamino)-oxomethyl]amino]-2-oxoethyl] ester	[no description available]	low	0	piperidines
2-methyl-2,6-diphenyl-7-oxa-1-azabicyclo[2.2.1]heptane	[no description available]	low	0	piperidines
N-(3-isoxazolyl)-3-nitro-4-(1-piperidinyl)benzamide	[no description available]	low	0	piperidines
N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide	[no description available]	low	0	piperidines
2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-quinazolinamine	[no description available]	low	0	piperidines
1-(4-carbamoyl-2-nitrophenyl)-4-piperidinecarboxylic acid methyl ester	[no description available]	low	0	piperidines
N-(1,3-benzodioxol-5-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide	[no description available]	low	0	piperidines
5-[2-furanyl-[4-(phenylmethyl)-1-piperidinyl]methyl]-6-thiazolo[3,2-b][1,2,4]triazolol	[no description available]	low	0	piperidines
5-nitro-6-(3-nitrophenyl)-2-piperidinone	[no description available]	low	0	piperidines
3-nitro-4-[2-[1-(phenylmethyl)-4-piperidinylidene]hydrazinyl]benzenesulfonamide	[no description available]	low	0	piperidines
pibutidine	[no description available]	low	0	aromatic ether; cyclobutenones; olefinic compound; piperidines; primary amino compound; pyridines; secondary amino compound	anti-ulcer drug; H2-receptor antagonist
N-[4-[(4-methyl-1-piperidinyl)methyl]phenyl]-1-[5-(1-pyrrolyl)-1,3,4-thiadiazol-2-yl]-4-piperidinecarboxamide	[no description available]	low	0	piperidines
palbociclib	[no description available]	low	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
1-(2-chlorophenyl)-3-[4-(1-piperidinylmethyl)phenyl]urea	[no description available]	low	0	piperidines
opc-67683	[no description available]	low	0	piperidines
ro 25-6981	[no description available]	low	0	benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound	anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist
pd 174494	[no description available]	low	0	piperidines
2-ethoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide	[no description available]	low	0	piperidines
n-demethylloperamide	[no description available]	low	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	drug metabolite
bms201038	[no description available]	low	0	(trifluoromethyl)benzenes; benzamides; fluorenes; piperidines	anticholesteremic drug; MTP inhibitor
casopitant	[no description available]	low	0	piperidines
pimavanserin	[no description available]	low	0	aromatic ether; monofluorobenzenes; piperidines; tertiary amino compound; ureas	5-hydroxytryptamine 2A receptor inverse agonist; antipsychotic agent; serotonergic antagonist
rolapitant	[no description available]	low	0	azaspiro compound; ether; organofluorine compound; piperidines; pyrrolidin-2-ones	antiemetic; neurokinin-1 receptor antagonist
at 7867	[no description available]	low	0	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
at 7519	[no description available]	low	0	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
alogliptin	[no description available]	low	0	nitrile; piperidines; primary amino compound; pyrimidines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
azd 8931	[no description available]	low	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
pf 00299804	[no description available]	low	0	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
dorsomorphin	[no description available]	low	0	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
6-o-desmethyl donepezil	[no description available]	low	0	piperidines
nvp-tae684	[no description available]	low	0	piperidines
[3-[(2-methylphenyl)methyl]-1-[(5-methyl-2-thiophenyl)methyl]-3-piperidinyl]methanol	[no description available]	low	0	piperidines
2-(2-fluoro-5-methoxyphenyl)-5-methyl-4-[(4-phenyl-1-piperidinyl)methyl]oxazole	[no description available]	low	0	piperidines
[3-[(3-chlorophenyl)methyl]-1-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-3-piperidinyl]methanol	[no description available]	low	0	piperidines
2-[4-[1-(2-fluorophenyl)-4-piperidinyl]-1-[(3-methoxyphenyl)methyl]-2-piperazinyl]ethanol	[no description available]	low	0	piperidines
[1-[(1,2-dimethyl-3-indolyl)methyl]-4-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]methanol	[no description available]	low	0	piperidines
[1-(2-benzofuranylmethyl)-4-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]methanol	[no description available]	low	0	piperidines
1-(5-isoquinolinylmethyl)-4-[(3-methoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester	[no description available]	low	0	piperidines
3-[[4-[(4-chlorophenyl)methyl]-4-(hydroxymethyl)-1-piperidinyl]-oxomethyl]-4,5-dihydro-1H-pyridazin-6-one	[no description available]	low	0	piperidines
1-(2-chloro-4-methylphenyl)-3-[[1-[(3-chlorophenyl)methyl]-4-piperidinyl]methyl]urea	[no description available]	low	0	piperidines
1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]thiourea	[no description available]	low	0	piperidines
3-hydroxy-2-(3-methylphenyl)-5-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-4-triazolimine	[no description available]	low	0	piperidines
4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine	[no description available]	low	0	piperidines
gdc-0973	[no description available]	low	0	aromatic amine; difluorobenzene; N-acylazetidine; organoiodine compound; piperidines; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
gsk690693	[no description available]	low	0	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
WAY-316606	[no description available]	low	0	(trifluoromethyl)benzenes; piperidines; secondary amino compound; sulfonamide; sulfone	secreted frizzled-related protein 1 inhibitor
N-butyl-4-(phenylmethyl)-1-piperidinecarbothioamide	[no description available]	low	0	piperidines
alcaftadine	[no description available]	low	0	aldehyde; imidazobenzazepine; piperidines; tertiary amino compound	anti-allergic agent; H1-receptor antagonist
N-(2-methylpropyl)-4-(phenylmethyl)-1-piperidinecarbothioamide	[no description available]	low	0	piperidines
4-(phenylmethyl)-N-prop-2-enyl-1-piperidinecarbothioamide	[no description available]	low	0	piperidines
N-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-4-piperidinyl]-3-pyrazolyl]-4-phenylbutanamide	[no description available]	low	0	piperidines
4-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinecarboxylic acid	[no description available]	low	0	carboxylic acid; piperidines
2-(2,6-dimethylphenoxy)-N-[2-(1-piperidinyl)phenyl]acetamide	[no description available]	low	0	piperidines
niraparib	[no description available]	low	0	benzenes; indazoles; piperidines; primary carboxamide	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ipi-926	[no description available]	low	0	piperidines
asp3026	[no description available]	low	0	aromatic amine; diamino-1,3,5-triazine; monomethoxybenzene; N-methylpiperazine; piperidines; secondary amino compound; sulfone	antimalarial; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
bix 01294	[no description available]	low	0	piperidines
pf 3845	[no description available]	low	0	piperidines
glasdegib	[no description available]	low	0	benzimidazoles; nitrile; phenylureas; piperidines	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
1-[3-methoxy-4-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]-4-piperidinol	[no description available]	low	0	piperidines
1-[4-[[4-amino-5-chloro-6-(2-propan-2-ylsulfonylanilino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-piperidinecarboxamide	[no description available]	low	0	piperidines
2,3-dimethoxy-N-[4-(1-piperidinyl)phenyl]aniline	[no description available]	low	0	piperidines
ulixacaltamide	[no description available]	low	0	benzamides; monochlorobenzenes; monofluorobenzenes; piperidines; secondary carboxamide	non-narcotic analgesic; T-type calcium channel blocker
Mps1-IN-2	[no description available]	low	0	piperidines
gilteritinib	[no description available]	low	0	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alectinib	[no description available]	low	0	aromatic ketone; morpholines; nitrile; organic heterotetracyclic compound; piperidines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
ceritinib	[no description available]	low	0	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gsk2879552	[no description available]	low	0	benzenes; benzoic acids; cyclopropanes; monocarboxylic acid; piperidines; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor
ldc4297	[no description available]	low	0	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
PF-06446846	[no description available]	low	0	benzamides; monochloropyridine; piperidines; tertiary carboxamide; triazolopyridine	antilipemic drug; EC 3.4.21.61 (kexin) inhibitor

isofagomine

Cross-References

Synonyms (35)

Research Excerpts

Overview

Drug Classes (1)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (72)

Molecular Functions (22)

Ceullar Components (21)

Bioassays (87)

Research

Studies (94)

Study Types

Condition	Relationship Strength	Studies
Acid beta-Glucosidase Deficiency	low	25
Acid beta-Glucosidase Deficiency Disease	low	25
Acute Neuronopathic Gaucher Disease	low	25
Adult GM1 Gangliosidosis	low	5
alpha-Galactosidase A Deficiency	low	1
alpha-Galactosidase A Deficiency Disease	low	1
Anderson-Fabry Disease	low	1
Angiokeratoma Corporis Diffusum	low	1
Angiokeratoma Diffuse	low	1
Angiokeratoma, Diffuse	low	1
Anoxia-Ischemia, Brain	low	1
Anoxia-Ischemia, Cerebral	low	1
Anoxic-Ischemic Encephalopathy	low	1
B16 Melanoma	low	1
beta Galactosidase 1 Deficiency	low	5
beta Galactosidase Deficiency	low	5
beta-Galactosidase Deficiency	low	5
Beta-Galactosidase-1 (GLB1) Deficiency	low	5
beta-Galactosidase-1 Deficiency	low	5
Beta-Galactosidase-1 Deficiency Disease	low	5
Beta-Galactosidosis	low	5
Brain Anoxia-Ischemia	low	1
Brain Hypoxia-Ischemia	low	1
Brain Inflammation	low	1
Brain Ischemia-Anoxia	low	1
Brain Ischemia-Hypoxia	low	1
Ceramide Trihexosidase Deficiency	low	1
Cerebral Anoxia-Ischemia	low	1
Cerebral Hypoxia-Ischemia	low	1
Cerebral Ischemia-Anoxia	low	1
Cerebral Ischemia-Hypoxia	low	1
Cerebroside Lipidosis Syndrome	low	25
Chronic Gaucher Disease	low	25
Classic Globoid Cell Leukodystrophy	low	1
Diarrhea	low	1
Diffuse Globoid Body Sclerosis	low	1
Disease Models, Animal	low	7
Early-Onset Globoid Cell Leukodystrophy	low	1
Eccentro-Osteochondrodysplasia	low	3
Eccentroosteochondrodysplasia	low	3
Encephalitis	low	1
Encephalitis, Rasmussen	low	1
Encephalopathy, Anoxic-Ischemic	low	1
Encephalopathy, Hypoxic-Ischemic	low	1
Experimental Melanoma	low	1
Experimental Melanomas	low	1
Fabry Disease	low	1
Fabry's Disease	low	1
G(M1) Gangliosidosis	low	5
Galactocerebrosidase Deficiency	low	1
Galactosamine-6-Sulfatase Deficiency	low	3
Galactosylceramidase Deficiency Disease	low	1
Galactosylceramide beta-Galactosidase Deficiency	low	1
Galactosylceramide Lipidosis	low	1
Galactosylceramide-beta-Galactosidase Deficiency Disease	low	1
Galactosylcerebrosidase Deficiency	low	1
Galactosylsphingosine Lipidosis	low	1
GALC Deficiency	low	1
GALNS Deficiency	low	3
Ganglioside Storage Diseases	low	1
Ganglioside Storage Disorders	low	1
Gangliosidoses	low	1
Gangliosidosis	low	1
Gangliosidosis G(M1)	low	5
Gangliosidosis Generalized GM1, Type 1	low	5
Gangliosidosis GM1	low	5
Gangliosidosis GM1 Type 3	low	5
Gangliosidosis GM1, Adult	low	5
Gangliosidosis GM1, Infantile	low	5
Gangliosidosis GM1, Juvenile	low	5
Gangliosidosis GM1, Type 1	low	5
Gangliosidosis GM1, Type 2	low	5
Gangliosidosis GM1, Type 3	low	5
Gangliosidosis, Generalized GM1 Type 2	low	5
Gangliosidosis, Generalized GM1, Adult Type	low	5
Gangliosidosis, Generalized GM1, Chronic Type	low	5
Gangliosidosis, Generalized GM1, Infantile Form	low	5
Gangliosidosis, Generalized GM1, Juvenile Type	low	5
Gangliosidosis, Generalized GM1, Type 1	low	5
Gangliosidosis, Generalized GM1, Type 2	low	5
Gangliosidosis, Generalized GM1, Type 3	low	5
Gangliosidosis, Generalized GM1, Type I	low	5
Gangliosidosis, Generalized GM1, Type II	low	5
Gangliosidosis, Generalized GM1, Type III	low	5
Gangliosidosis, GM1	low	5
Gaucher Disease	low	25
Gaucher Disease Type 1	low	25
Gaucher Disease Type 2	low	25
Gaucher Disease Type 3	low	25
Gaucher Disease, Acute Neuronopathic	low	25
Gaucher Disease, Acute Neuronopathic Type	low	25
Gaucher Disease, Chronic	low	25
Gaucher Disease, Chronic Neuronopathic Type	low	25
Gaucher Disease, Infantile	low	25
Gaucher Disease, Infantile Cerebral	low	25
Gaucher Disease, Juvenile	low	25
Gaucher Disease, Juvenile and Adult, Cerebral	low	25
Gaucher Disease, Neuronopathic	low	25
Gaucher Disease, Non-Neuronopathic Form	low	25
Gaucher Disease, Noncerebral Juvenile	low	25
Gaucher Disease, Subacute Neuronopathic Form	low	25
Gaucher Disease, Subacute Neuronopathic Type	low	25
Gaucher Disease, Type 1	low	25
Gaucher Disease, Type 2	low	25
Gaucher Disease, Type 3	low	25
Gaucher Disease, Type I	low	25
Gaucher Disease, Type II	low	25
Gaucher Disease, Type III	low	25
Gaucher Splenomegaly	low	25
Gaucher Syndrome	low	25
Gaucher's Disease	low	25
Gauchers Disease	low	25
GBA Deficiency	low	25
Generalized Gangliosidosis	low	5
GLA Deficiency	low	1
GLB1 Deficiency	low	5
Globoid Body Sclerosis, Diffuse	low	1
Globoid Cell Leukodystrophy	low	1
Globoid Cell Leukoencephalopathy	low	1
Globoid Leukodystrophy	low	1
Glucocerebrosidase Deficiency	low	25
Glucocerebrosidase Deficiency Disease	low	25
Glucocerebrosidosis	low	25
Glucosyl Cerebroside Lipidosis	low	25
Glucosylceramidase Deficiency	low	25
Glucosylceramide Beta-Glucosidase Deficiency	low	25
Glucosylceramide Beta-Glucosidase Deficiency Disease	low	25
Glucosylceramide Lipidosis	low	25
GM1 Gangliosidosis	low	5
GM1-Gangliosidosis, Type I	low	5
GM1-Gangliosidosis, Type II	low	5
GM1-Gangliosidosis, Type III	low	5
Harding Passey Melanoma	low	1
Hereditary Dystopic Lipidosis	low	1
Hypoxia-Ischemia, Brain	low	1
Hypoxia-Ischemia, Cerebral	low	1
Hypoxic-Ischemic Encephalopathy	low	1
Idiopathic Parkinson Disease	low	4
Idiopathic Parkinson's Disease	low	4
Infantile Gaucher Disease	low	25
Infantile Globoid Cell Leukodystrophy	low	1
Inflammation	low	1
Inflammation, Brain	low	1
Innate Inflammatory Response	low	1
Ischemia-Anoxia, Brain	low	1
Ischemia-Anoxia, Cerebral	low	1
Ischemia-Hypoxia, Brain	low	1
Ischemia-Hypoxia, Cerebral	low	1
Ischemic-Hypoxic Encephalopathy	low	1
Kerasin Histiocytosis	low	25
Kerasin Lipoidosis	low	25
Kerasin thesaurismosis	low	25
Kidney Failure	low	1
Kidney Insufficiency	low	1
Krabbe Disease	low	1
Krabbe Leukodystrophy	low	1
Krabbe's Disease	low	1
Krabbe's Leukodystrophy	low	1
Late-Onset Globoid Cell Leukodystrophy	low	1
Leukodystrophy, Globoid Cell	low	1
Leukodystrophy, Globoid Cell, Classic	low	1
Leukodystrophy, Globoid Cell, Early-Onset	low	1
Leukodystrophy, Globoid Cell, Infantile	low	1
Leukodystrophy, Globoid Cell, Late-Onset	low	1
Lewy Body Parkinson Disease	low	4
Lewy Body Parkinson's Disease	low	4
Lipoid Histiocytosis (Kerasin Type)	low	25
Lysosomal Enzyme Disorders	low	3
Lysosomal Storage Diseases	low	3
Melanoma, B16	low	1
Melanoma, Cloudman S91	low	1
Melanoma, Experimental	low	1
Melanoma, Harding-Passey	low	1
Melanomas, Experimental	low	1
Morquio A Disease	low	3
Morquio B Syndrome	low	3
Morquio Disease	low	3
Morquio Syndrome	low	3
Morquio Syndrome A	low	3
Morquio Syndrome B	low	3
Morquio Syndrome, Type B	low	3
Morquio-B Disease	low	3
Morquio's Disease	low	3
Morquio's Disease Type B	low	3
Morquio's Syndrome	low	3
MPS IV A	low	3
MPS IV B	low	3
MPS IVA	low	3
MPS IVB	low	3
Mucopolysaccharidosis 4	low	3
Mucopolysaccharidosis 4B	low	3
Mucopolysaccharidosis IV	low	3
Mucopolysaccharidosis Type IV	low	3
Mucopolysaccharidosis Type IV A	low	3
Mucopolysaccharidosis Type IV B	low	3
Mucopolysaccharidosis Type IVA	low	3
Mucopolysaccharidosis Type IVB	low	3
Neuronopathic Gaucher Disease	low	25
Non-Neuronopathic Gaucher Disease	low	25
Paralysis Agitans	low	4
Parkinson Disease	low	4
Parkinson Disease, Idiopathic	low	4
Parkinson's Disease	low	4
Parkinson's Disease, Idiopathic	low	4
Parkinson's Disease, Lewy Body	low	4
Primary Parkinsonism	low	4
Psychosine Lipidosis	low	1
Rasmussen Encephalitis	low	1
Rasmussen Syndrome	low	1
Rasmussen's Syndrome	low	1
Renal Failure	low	1
Renal Insufficiency	low	1
Subacute Neuronopathic Gaucher Disease	low	25
Type 1 Gaucher Disease	low	25
Type 2 Gaucher Disease	low	25
Type 3 (Adult) GM1 Gangliosidosis	low	5
Type 3 Gaucher Disease	low	25

isofagomine

Cross-References

Synonyms (35)

Research Excerpts

Overview

Drug Classes (1)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (72)

Molecular Functions (22)

Ceullar Components (21)

Bioassays (87)

Research

Studies (94)

Study Types

Related Drugs (305)

Related Conditions (217)